Inovio Pharmaceuticals (NASDAQ:INO) Announces Earnings Results

Inovio Pharmaceuticals (NASDAQ:INO) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio said its INO-3107 BLA remains on track for the October 30, 2026 PDUFA date, and the FDA’s mid-cycle review raised no new significant issues. Management also said the agency reiterated plans to schedule the informal meeting on accelerated-approval eligibility.
• The company continues to believe INO-3107 supports accelerated approval based on its phase I/II data, citing large reductions in surgeries, a favorable safety profile, and a differentiated mechanism that may help patients not served by the current approved therapy.
• Inovio is building commercial readiness ahead of a potential launch, including partnerships for logistics, specialty distribution, pharmacy, and patient support. Management said it plans to commercialize with a contract sales organization and expects to benefit from learnings from the competitor’s launch.
• The company strengthened its balance sheet with a April equity offering that raised about $16 million net. Inovio ended Q1 with $37.7 million in cash and short-term investments and said its runway now extends into Q1 2027, beyond the expected PDUFA date.
• Beyond INO-3107, Inovio highlighted progress on its broader pipeline, including an Akeso/Dana-Farber collaboration in glioblastoma and advancement of its DPROT platform for rare-disease applications such as hemophilia A, Fabry disease, and hypophosphatasia.

Inovio Pharmaceuticals Price Performance

Shares of Inovio Pharmaceuticals stock traded down $0.03 on Friday, reaching $1.33. 744,771 shares of the company were exchanged, compared to its average volume of 1,992,721. Inovio Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $2.98. The company has a market cap of $92.49 million, a P/E ratio of -0.91 and a beta of 1.43. The stock’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.71.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Focus Partners Wealth acquired a new position in Inovio Pharmaceuticals in the third quarter valued at approximately $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Inovio Pharmaceuticals by 752.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 18,160 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in Inovio Pharmaceuticals by 4,396.0% in the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Inovio Pharmaceuticals in the third quarter valued at approximately $41,000. 26.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on INO shares. Oppenheimer reiterated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.50.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.